New hope for advanced cancer patients: first human trial of SIM0609 begins
NCT ID NCT07265921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called SIM0609 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 232 participants will take part across multiple centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Hubei Cancer Hospital
NOT_YET_RECRUITINGWuhan, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, China
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITINGShanghai, China
-
Tianjin Cancer Hospital
NOT_YET_RECRUITINGTianjin, China
-
Zhongshan Hospital，Fudan University
NOT_YET_RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Experimental drug JS015 takes first steps against advanced solid tumors
- New experimental drug SIM0613 enters first human tests for advanced cancers
- New drug INV-6452 targets Hard-to-Treat breast cancers
- New drug combo aims to fight advanced cancers in first human trial
- New drug targets Hard-to-Treat cancer mutation in first human trial